IMMUTOL Project 

(Advanced Antigen-Specific Dendritic Cell-Based Therapy to Re-establish Tolerance in Immune-Mediated Diseases) 

About the Project 

IMMUTOL is a Horizon Europe-funded project (Grant Agreement ID: 101080562) aiming to develop an innovative, antigen-specific dendritic cell-based therapy to restore immune tolerance in immune-mediated diseases, including Multiple Sclerosis (MS).
By advancing cutting-edge research, IMMUTOL seeks to improve treatment options and quality of life for people living with chronic immune conditions. 

Learn more on the official website: immutol-horizon.eu 

EMSP’s Role 

As a partner in IMMUTOL, EMSP ensures that the voices and experiences of people with MS are at the heart of the project. Our activities include: 

• Patient consultations through the MS Community Advisory Board (MS CAB) on trial design, ethics, and regulatory aspects. 

• Developing and sharing communication materials (brochures, videos, social media content) to explain the project in accessible language. 

• Organising webinars and workshops with our network of MS organisations across Europe. 

• Representing people with MS in annual IMMUTOL project meetings. 

• Collecting patient feedback and sharing it with researchers to shape the project outcomes. 

Through these efforts, EMSP supports meaningful patient engagement and ensures the project remains aligned with the real needs of the MS community. 

Timeline 

IMMUTOL runs from 2025 to 2027. During this time, EMSP will: 

• Host community consultations and webinars. 

• Share project updates through our newsletter, social media, and events. 

• Contribute to developing accessible tools and materials for patients.